C arbapenems are often used as a last resort for treating serious infections attributable to multidrug-resistant gram-negative bacilli because these drugs are stable even to extended-spectrum and AmpC β-lactamases. However, gram-negative bacilli with acquired metallo-β-lactamase (MBL), IMP-1, emerged and spread during the early 1990s in Japan (1) . IMP-1 and its variants were then detected in other countries (2) .
Another type of acquired MBL, VIM-1, was first reported in Pseudomonas aeruginosa in Italy (3), followed by reports of VIM-2 in France and Greece. VIM-2 was detected in P. aeruginosa in a Korean hospital isolated as early as 1995 (4) . The occurrence of the VIM enzyme has continued to evolve: VIM-3 was reported in Taiwan (5) , and VIM-4 in the United States (6) .
The bla IMP and bla VIM genes are horizontally transferable because they are inserted in integrons, and some of these integrons are located on conjugative plasmids (7) . Because of its ability to spread, carbapenem resistance related to IMP and VIM β-lactamase production has become a serious concern (8) . Laboratory personnel and physicians must consider the therapeutic and infectioncontrol implications of not detecting carbapenemase-producing bacteria (9) . A large number of VIM-2-producing Pseudomonas spp. have been detected in a Korean hospital since 1995 (4), but the occurrence of MBL-producing isolates has not been studied at other Korean hospitals, despite the high prevalence of carbapenem-resistant P. aeruginosa and Acinetobacter spp. (10) . The aim of our study was to determine the occurrence of acquired MBLproducing P. aeruginosa and Acinetobacter spp. among isolates collected by Korean Nationwide Surveillance of Antimicrobial Resistance Group hospitals. The MBL types produced and the sources of the MBL-positive isolates were also investigated. In addition, pulsed-field gel electrophoresis (PFGE) patterns were compared to determine intra-and inter-hospital spread of resistant strains.
The Study
Nonduplicate, imipenem-resistant isolates of 387 Pseudomonas spp. and 267 Acinetobacter spp. were collected from 2000 to 2001 from 28 hospitals in the Korean Nationwide Surveillance of Antimicrobial Resistance Group hospitals located in six cities or provinces. The identification of the species and the imipenem susceptibility were confirmed at the coordinating laboratory by using conventional tests (11) or ATB 32 GN system (bioMerieux, Marcy-l'Etoile, France) and by using the disk diffusion test (12) , respectively. MBL production was screened by using the Hodge test and the imipenem-EDTA double disk synergy test (13) . The bla IMP-1 and bla VIM-2 alleles were detected by polymerase chain reaction (PCR), and three of the positive isolates were confirmed by sequencing, as described previously (4). XbaI-digested genomic DNA of P. aeruginosa isolates was separated by PFGE using the CHEF-DR-II system (Bio-Rad Laboratories, Hercules, CA) (4). The pattern was analyzed visually and by using UVIBand and Map software (UVItec Ltd., Cambridge, UK).
Some of the Pseudomonas and Acinetobacter isolates collected were not fully resistant to imipenem but showed intermediate resistance when retested. Among the isolates not susceptible to imipenem, 44 (11.4%) of 387 Pseudomonas spp. (42 P. aeruginosa and 2 P. putida) and 38 (14.2%) of 267 Acinetobacter spp. were considered MBL producers on the basis of positive results by the Hodge test and imipenem-EDTA double disk synergy test (Table 1) . MBL-producing Pseudomonas spp. and Acinetobacter spp. were detected in 11 (52.4%) of 21 and 10 (41.7%) of 24 hospitals that were located in four of five and five of six cities or provinces, respectively. We detected the bla VIM allele by PCR from all 42 isolates of MBLproducing P. aeruginosa and 2 isolates of P. putida. The bla VIM-2 and bla IMP-1 alleles were detected in 27 (71.1%) and 11 (28.9%) of 38 Acinetobacter isolates, respectively (Table 2) . Nucleotide sequencing for three representative PCR-positive isolates confirmed the presence of the bla VIM-2 gene in one isolate each of P. aeruginosa and Acinetobacter spp., and the bla IMP-1 gene in one isolate of Acinetobacter spp.
The MBL-producing strains were isolated mainly from intensive-care unit patients (31.7%) and other inpatients (50.0%); five (6.1%) were from emergency service and other outpatients (Table 3) . Overall, MBL-producing isolates were mainly obtained from specimens of sputum (50.0%) and urine (29.3%). However, the proportion of MBL-producing isolates was relatively higher among urine isolates: 17.3% for Pseudomonas spp. and 29.2% for Acinetobacter spp. We obtained one MBL-producing Acinetobacter isolate from each of the following specimen types: blood, spinal fluid, pleural fluid, and venous catheter tip (Table 4 ).
The PFGE of the XbaI-digested genomic DNA of 39 isolates of P. aeruginosa showed 22 patterns (data not shown). Six isolates from one hospital had an identical pattern. Thirteen isolates (33.3%) belonged to another identical pattern-six from one hospital, two from each of two hospitals, and one from each of three hospitals, which were located in a city and two provinces.
Conclusions
In this study, >10% of all imipenem-nonsusceptible isolates of Pseudomonas spp. and Acinetobacter spp. were attributable to MBL production (Table 1) , and these MBLproducing isolates were detected in 62.5% of the participating hospitals. Our finding indicates that MBL-producing P. aeruginosa is more prevalent in Korea than in other countries (2) and that MBL-producing Acinetobacter spp. is increasing. The percentage of hospitals with MBL-producing isolates might have been higher if a larger number of imipenem-nonsusceptible isolates had been collected for this study.
VIM-2 was the only type of acquired MBL identified initially in Korea. VIM-2-producing P. aeruginosa was isolated at almost the same time in Europe (7) and Korea (4). However, IMP-1-producing isolates were rare until 2000 in Korea. Only one and three IMP-1-positive P. aeruginosa and Acinetobacter spp., respectively, have been isolated at the coordinating laboratory (4, unpub. data). In our study, 11 (28.9%) of 38 MBL-positive isolates of Acinetobacter spp. were IMP producers ( Table 2 ). This increase suggests the possible introduction of IMP-producing strains of Acinetobacter spp. from Japan, where 28 isolates of bla IMP-1 -positive Acinetobacter baumannii were reported in a hospital as early as 1994 to 1996 (14) .
Rasmussen and Bush (15) predicted that an increase of MBL-producing organisms was inevitable, given the more frequent use of carbapenems. Imipenem has been used for Acinetobacter spp. are also common nosocomial pathogens with multidrug resistance. The imipenem resistance rate of this organism isolated in Korea was found to be much lower than that of P. aeruginosa, but its resistance rate rose from 4% in the first quarter to 20% in the third quarter of 2002 at the coordinating laboratory (data not shown).
In our study, MBL-producing Pseudomonas spp. and Acinetobacter spp. were isolated mainly from sputum and urine specimens, and most (81.7%) isolates were from inpatients and intensive-care unit patients. Therefore, proper treatment of respiratory secretions and urine from intensive-care unit patients is considered an important aspect of preventing the spread of MBL-producing organisms. The presence of P. aeruginosa isolates with identical PFGE patterns among those collected not only from certain hospitals but also from different hospitals suggests that clonal spread is at least a part of the cause of intra-and inter-hospital dissemination of MBL-producing isolates. The presence of VIM-2-producing Serratia marcescens, Enterobacter cloacae, and Achromobacter xylosoxidans subsp. denitrificans (unpub. data) in other hospitals also suggests horizontal transfer of the resistance determinants.
Cornaglia et al. reported that five of seven patients infected with MBL-producing P. aeruginosa died, although the cause of death was difficult to establish with certainty (16) . Clinical studies on the infection are rare because isolation of MBL-producing gram-negative bacilli increased only recently. We anticipate difficulties in treating patients infected with MBL-producing gram-negative bacilli, which can hydrolyze, in vitro, all available β-lactams, except aztreonam for which clinical efficacy is unknown.
Our study indicates the urgent need for action to prevent further spread of MBL-producing organisms. Previous experiences with penicillin-nonsusceptible pneumococci, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and extendedspectrum β-lactamase-producing Klebsiella pneumoniae indicate that once resistant bacteria can become widespread they cannot be controlled (10) . Our first task is to detect MBL producers among clinical isolates (9) . Although the National Committee for Clinical Laboratory Standards document (12) does not contain procedures for detection, simple procedures are available (13) .
The prevalence of bla VIM-2 allele-positive P. aeruginosa and bla IMP-1 allele-positive Acinetobacter spp. is increasing possibly because of clonal and horizontal spread of the resistance determinant in Korean hospitals. Sputum and urine from inpatients and intensive-care unit patients were found to be the main sources of MBL-producing isolates. Laboratories not only in Korea but also in other countries with carbapenem-resistant organisms must be prepared to screen MBL-producing isolates to determine the clinical impact and prevent further spread of MBL-producing organisms.
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